|
US5080898A
(en)
|
1982-05-12 |
1992-01-14 |
The University Hospital |
Enzymatically active toxin coupled to a cell-specific ligand
|
|
US5668255A
(en)
|
1984-06-07 |
1997-09-16 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
|
US6022950A
(en)
|
1984-06-07 |
2000-02-08 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
|
US5091178A
(en)
|
1986-02-21 |
1992-02-25 |
Oncogen |
Tumor therapy with biologically active anti-tumor antibodies
|
|
US7838216B1
(en)
|
1986-03-05 |
2010-11-23 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Human gene related to but distinct from EGF receptor gene
|
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク，インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
|
US5135736A
(en)
|
1988-08-15 |
1992-08-04 |
Neorx Corporation |
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
|
|
DE69031120T2
(de)
|
1989-05-19 |
1998-01-15 |
Genentech, Inc., South San Francisco, Calif. |
Her2 extrazellulare domäne
|
|
WO1991009871A1
(en)
|
1989-12-22 |
1991-07-11 |
Seragen Incorporated |
Hybrid molecules having translocation region and cell-binding region
|
|
US5578482A
(en)
|
1990-05-25 |
1996-11-26 |
Georgetown University |
Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
|
|
US5635384A
(en)
|
1990-06-11 |
1997-06-03 |
Dowelanco |
Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
|
|
IL101943A0
(en)
|
1991-05-24 |
1992-12-30 |
Genentech Inc |
Structure,production and use of heregulin
|
|
US5834229A
(en)
|
1991-05-24 |
1998-11-10 |
Genentech, Inc. |
Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US6146850A
(en)
|
1991-11-04 |
2000-11-14 |
Xoma Corporation |
Proteins encoding gelonin sequences
|
|
WO1994026910A1
(en)
|
1993-05-12 |
1994-11-24 |
Xoma Corporation |
Immunotoxins comprising gelonin and an antibody
|
|
US5621083A
(en)
|
1991-11-04 |
1997-04-15 |
Xoma Corporation |
Immunotoxins comprising ribosome-inactivating proteins
|
|
AU4025193A
(en)
|
1992-04-08 |
1993-11-18 |
Cetus Oncology Corporation |
Humanized C-erbB-2 specific antibodies
|
|
AU687346B2
(en)
|
1992-06-30 |
1998-02-26 |
Oncologix, Inc. |
A combination of anti-erbB-2 monoclonal antibodies and method of using
|
|
FR2697695B1
(fr)
|
1992-11-04 |
1995-01-13 |
Cachan Ecole Normale Superieur |
Dispositif de conversion électromécanique produisant un mouvement en particulier linéaire.
|
|
US5869445A
(en)
|
1993-03-17 |
1999-02-09 |
University Of Washington |
Methods for eliciting or enhancing reactivity to HER-2/neu protein
|
|
CA2218601A1
(en)
|
1995-03-24 |
1996-10-03 |
Ophidian Pharmaceuticals, Inc. |
Treatment for verotoxin-producing escherichia coli
|
|
US5667786A
(en)
|
1995-06-07 |
1997-09-16 |
Novavax, Inc. |
Method for treating tumors with a toxin
|
|
US5977322A
(en)
|
1995-06-14 |
1999-11-02 |
The Regents Of The University Of California |
High affinity human antibodies to tumor antigens
|
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
|
US5858682A
(en)
|
1996-08-02 |
1999-01-12 |
Pharmingen |
E2A/pbx1 fusion protein specific monoclonal antibodies
|
|
EP0921167A4
(en)
|
1996-08-22 |
2000-01-12 |
Kaneka Corp |
CURABLE COMPOSITION FOR EXTERIOR COATING AND ARTICLES THEREOF COVERED
|
|
AU723268B2
(en)
|
1996-09-09 |
2000-08-24 |
Zealand Pharma A/S |
Improved solid-phase peptide synthesis and agent for use in such synthesis
|
|
JP2001500730A
(ja)
|
1996-09-10 |
2001-01-23 |
ヘンリー エム ジャクソン ファンデーション フォージ アドバンスメント オブ ミリタリー メディシン |
ヒスチジン―タグ付き志賀毒素およびトキソイド、該毒素およびトキソイドとの融合タンパク質ならびにそれらの精製及び調製方法
|
|
US5770380A
(en)
|
1996-09-13 |
1998-06-23 |
University Of Pittsburgh |
Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
|
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
FR2766193B1
(fr)
|
1997-07-18 |
2001-09-14 |
Inst Curie |
Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
|
|
CA2222993A1
(en)
|
1998-02-04 |
1999-08-04 |
The Ontario Cancer Institute |
A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries
|
|
WO1999062526A2
(en)
|
1998-06-05 |
1999-12-09 |
Mayo Foundation For Medical Education And Research |
Use of genetically engineered antibodies to cd38 to treat multiple myeloma
|
|
US7157418B1
(en)
|
1998-07-22 |
2007-01-02 |
Osprey Pharmaceuticals, Ltd. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
|
DE69910216T2
(de)
|
1998-07-22 |
2004-02-19 |
Osprey Pharmaceuticals Ltd., Calgary |
Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
|
|
US6770456B1
(en)
|
1998-07-29 |
2004-08-03 |
Ludwig Institute For Cancer Research |
Endogenous retrovirus tumor associated nucleic acids and antigens
|
|
AU5963699A
(en)
|
1998-10-02 |
2000-04-26 |
Mcmaster University |
Spliced form of (erb)b-2/neu oncogene
|
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
AU779612C
(en)
|
1999-07-02 |
2005-12-15 |
Genentech Inc. |
Peptide compounds that bind HER2
|
|
US6492498B1
(en)
|
1999-11-15 |
2002-12-10 |
Regents Of The University Of Minnesota |
Multimeric immunotoxins
|
|
US20010031485A1
(en)
|
2000-03-22 |
2001-10-18 |
Sibtech, Inc. |
Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
|
|
US7267973B2
(en)
|
2000-03-22 |
2007-09-11 |
Sibtech, Inc. |
Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor
|
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
WO2003055439A2
(en)
|
2001-07-18 |
2003-07-10 |
The Regents Of The University Of California |
Her2/neu target antigen and use of same to stimulate an immune response
|
|
AU2003208097A1
(en)
|
2002-02-04 |
2003-09-02 |
Hideo Yoshida |
Anticancer agents using vero toxin variants
|
|
US20040248151A1
(en)
|
2002-04-05 |
2004-12-09 |
Ventana Medical Systems, Inc. |
Method for predicting the response to HER2-directed therapy
|
|
EP2289942B1
(en)
|
2002-04-10 |
2013-07-31 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
|
US7449480B2
(en)
|
2002-05-14 |
2008-11-11 |
Baylor College Of Medicine |
Small molecule inhibitors of HER2 expression
|
|
US7019017B2
(en)
|
2002-05-14 |
2006-03-28 |
Baylor College Of Medicine |
Small molecule inhibitors of HER2 expression
|
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
|
AU2003303374A1
(en)
|
2002-12-20 |
2004-07-22 |
The Johns Hopkins University |
Treatment of metastatic cancer with the b-subunit of shiga toxin
|
|
EP1583833A1
(en)
|
2003-01-03 |
2005-10-12 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Rhesus her2/neu, nucleotides encoding same, and uses thereof
|
|
WO2005000902A1
(en)
|
2003-06-30 |
2005-01-06 |
Mu-Hyeon Choe |
The dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
|
|
CA2531238C
(en)
|
2003-07-04 |
2015-02-24 |
Affibody Ab |
Polypeptides having binding affinity for her2
|
|
US7674460B2
(en)
|
2003-08-01 |
2010-03-09 |
A&G Pharmaceutical, Inc. |
Compositions and methods for restoring sensitivity to treatment with HER2 antagonists
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
US7982011B2
(en)
|
2003-11-25 |
2011-07-19 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Mutated anti-cd22 antibodies and immunoconjugates
|
|
EP1687016A4
(en)
|
2003-11-25 |
2009-07-29 |
Anjin Corp |
GENETIC VARIANT OF DIPHTHERIC TOXIN
|
|
EP1727827B1
(en)
|
2004-03-26 |
2010-05-12 |
Molecular Templates, Inc. |
Library of toxin mutants, and methods of using same
|
|
DK1771482T3
(da)
|
2004-07-22 |
2014-10-20 |
Genentech Inc |
HER2-antistofsammensætning
|
|
JP5225069B2
(ja)
|
2005-03-23 |
2013-07-03 |
ゲンマブ エー／エス |
多発性骨髄腫の治療のためのｃｄ３８に対する抗体
|
|
US7771955B2
(en)
|
2005-06-09 |
2010-08-10 |
University Of Maryland |
Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
FI20055417A0
(fi)
|
2005-07-20 |
2005-07-20 |
Glykos Finland Oy |
Syöpäpesifiset glykaanit ja niiden käyttö
|
|
RU2421242C2
(ru)
|
2005-07-25 |
2011-06-20 |
Трабьон Фармасьютикалз, Инк. |
Применение однократной дозы cd20-специфических связывающих молекул
|
|
EP1945660B1
(en)
|
2005-09-26 |
2014-05-07 |
Molecular Templates, Inc. |
Library from toxin mutants, and methods of using same
|
|
WO2007071061A1
(en)
|
2005-12-23 |
2007-06-28 |
Viventia Biotech Inc. |
Methods for generating and screening fusion protein libraries and uses thereof
|
|
ES2532985T3
(es)
|
2006-02-16 |
2015-04-06 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Proteínas quiméricas de toxoide de Shiga
|
|
EP2097529A4
(en)
|
2006-12-29 |
2010-03-24 |
Osprey Pharmaceuticals Usa Inc |
METHOD FOR SELECTION AND PRODUCTION OF MODIFIED TOXINS, MODIFIED TOXINE CONJUGATES AND USES THEREOF
|
|
CA2689602A1
(en)
|
2007-06-06 |
2008-12-18 |
Avi Biopharma, Inc. |
Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
|
|
AU2008279550B2
(en)
|
2007-06-21 |
2012-08-09 |
Angelica Therapeutics, Inc. |
Modified toxins
|
|
US7887801B2
(en)
|
2007-07-13 |
2011-02-15 |
Topotarget Germany Ag |
Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
|
|
EP2187971A2
(en)
|
2007-08-01 |
2010-05-26 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
A fold-back diabody diphtheria toxin immunotoxin and methods of use
|
|
WO2009032954A1
(en)
|
2007-09-04 |
2009-03-12 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
|
|
US20100298238A1
(en)
|
2007-10-08 |
2010-11-25 |
Rutgers, The State University |
Nontoxic shiga-like toxin mutant compositions and methods
|
|
CA2705289A1
(en)
|
2007-11-13 |
2009-05-22 |
The Scripps Research Institute |
Production of cytotoxic antibody-toxin fusion in eukaryotic algae
|
|
EP2650311A3
(en)
|
2007-11-27 |
2014-06-04 |
Ablynx N.V. |
Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
|
|
US8315343B2
(en)
|
2007-12-17 |
2012-11-20 |
Telefonaktiebolaget Lm Ericsson (Publ) |
Multi-antenna receiver interference cancellation method and apparatus
|
|
EP2072525A1
(en)
|
2007-12-21 |
2009-06-24 |
Affibody AB |
New polypeptides having affinity for HER2
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
WO2009110944A1
(en)
|
2008-02-29 |
2009-09-11 |
Angelica Therapeutics, Inc. |
Modified toxins
|
|
ES2342646B1
(es)
|
2008-06-02 |
2011-04-26 |
Institut De Recerca Hospital Universitari Vall Hebron |
Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
|
|
CN102159243B
(zh)
|
2008-07-21 |
2015-08-19 |
免疫医疗公司 |
用于改良的治疗特征的抗体的结构变体
|
|
WO2010014595A2
(en)
|
2008-07-31 |
2010-02-04 |
The Ohio State University Research Foundation |
Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
|
|
US20100093563A1
(en)
|
2008-09-22 |
2010-04-15 |
Robert Anthony Williamson |
Methods and vectors for display of molecules and displayed molecules and collections
|
|
WO2010085539A1
(en)
|
2009-01-23 |
2010-07-29 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Methods and compositions based on shiga toxin type 2 protein
|
|
AU2010240569A1
(en)
|
2009-04-20 |
2011-10-20 |
Pfizer Inc. |
Control of protein glycosylation and compositions and methods relating thereto
|
|
JP2012533587A
(ja)
|
2009-07-22 |
2012-12-27 |
セニックス バイオサイエンス ゲーエムベーハー |
自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート
|
|
US9174169B2
(en)
|
2009-08-14 |
2015-11-03 |
Unifrax I Llc |
Mounting mat for exhaust gas treatment device
|
|
EP2371864A1
(en)
|
2010-03-23 |
2011-10-05 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
|
WO2011130580A1
(en)
|
2010-04-15 |
2011-10-20 |
Alper Biotech, Llc |
Monoclonal antibodies against her2 antigens, and uses therefor
|
|
EP2576621B1
(en)
|
2010-05-27 |
2019-04-10 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
GB201013989D0
(en)
|
2010-08-20 |
2010-10-06 |
Univ Southampton |
Biological materials and methods of using the same
|
|
PL219845B1
(pl)
|
2011-01-05 |
2015-07-31 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
|
US20140065172A1
(en)
|
2011-01-26 |
2014-03-06 |
Cenix Bioscience Gmbh |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
|
WO2012104344A1
(en)
|
2011-02-01 |
2012-08-09 |
Genmab A/S |
Human antibodies and antibody-drug conjugates against cd74
|
|
US8895006B2
(en)
|
2011-03-04 |
2014-11-25 |
Rutgers, The State University Of New Jersey |
Ricin ribosome binding protein compositions and methods of use thereof
|
|
SG194787A1
(en)
|
2011-05-06 |
2013-12-30 |
Us Gov Health & Human Serv |
Recombinant immunotoxin targeting mesothelin
|
|
PL397167A1
(pl)
|
2011-11-28 |
2013-06-10 |
Adamed Spólka Z Ograniczona Odpowiedzialnoscia |
Przeciwnowotworowe bialko fuzyjne
|
|
CA2865243A1
(en)
*
|
2012-02-23 |
2013-08-29 |
President And Fellows Of Harvard College |
Modified microbial toxin receptor for delivering agents into cells
|
|
EP3666795A1
(en)
|
2013-03-12 |
2020-06-17 |
Molecular Templates, Inc. |
Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
|
|
GB2519786A
(en)
|
2013-10-30 |
2015-05-06 |
Sergej Michailovic Kiprijanov |
Multivalent antigen-binding protein molecules
|
|
CN112851769A
(zh)
|
2014-01-27 |
2021-05-28 |
分子模板公司 |
用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
|
|
US20210138076A2
(en)
|
2014-01-27 |
2021-05-13 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
|
US20160177284A1
(en)
|
2014-01-27 |
2016-06-23 |
Molecular Templates, Inc. |
Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
|
|
WO2015120058A2
(en)
|
2014-02-05 |
2015-08-13 |
Molecular Templates, Inc. |
Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
|
|
JP6935195B2
(ja)
|
2014-03-11 |
2021-09-15 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
|
|
US11142584B2
(en)
|
2014-03-11 |
2021-10-12 |
Molecular Templates, Inc. |
CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
|
|
ES2809729T3
(es)
|
2014-03-11 |
2021-03-05 |
Molecular Templates Inc |
Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
|
|
TWI674257B
(zh)
|
2014-03-14 |
2019-10-11 |
日商拉夸里亞創藥股份有限公司 |
作為ｔｒｐｍ８拮抗劑之氮雜螺衍生物
|
|
CN106604934A
(zh)
|
2014-06-11 |
2017-04-26 |
分子模板公司 |
耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
|
|
ES2806776T3
(es)
|
2014-06-18 |
2021-02-18 |
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus |
Células NK-92 que expresan CAR como agentes terapéuticos celulares
|
|
CN105713087B
(zh)
|
2014-11-12 |
2020-05-08 |
北京康乐卫士生物技术股份有限公司 |
人乳头瘤病毒58型单克隆抗体及其应用
|
|
EP3253799B1
(en)
|
2015-02-05 |
2020-12-02 |
Molecular Templates, Inc. |
Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
|
|
EP3957738A1
(en)
|
2015-03-04 |
2022-02-23 |
IGM Biosciences, Inc. |
Cd20 binding molecules and uses thereof
|
|
EP3303373B1
(en)
*
|
2015-05-30 |
2020-04-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
KR20180030085A
(ko)
|
2015-07-26 |
2018-03-21 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
EP3202783A1
(en)
|
2016-02-02 |
2017-08-09 |
Ecole Polytechnique Fédérale de Lausanne (EPFL) |
Engineered antigen presenting cells and uses thereof
|
|
ES2883297T3
(es)
|
2016-03-29 |
2021-12-07 |
Stcube Inc |
Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
WO2018080812A1
(en)
|
2016-10-30 |
2018-05-03 |
Henlix, Inc. |
Anti-pd-l1 antibodies and variants
|
|
WO2018106895A1
(en)
*
|
2016-12-07 |
2018-06-14 |
Molecular Templates, Inc. |
Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
|
|
EP3434693A4
(en)
|
2016-12-26 |
2019-10-02 |
Dankook University Cheonan Campus Industry Academic Cooperation Foundation |
COMPOSITION FOR THE DIFFERENTIATION OF DENTAL STRAIN CELLS IN ODONTOBLAST FIELD CELLS AND MONOCLONAL IGG OR IGM-TYPE ANTIBODIES WITH SPECIFIC BINDING TO SURFACES OF ODOBOBLAST FIELD CELLS
|
|
MX2019008348A
(es)
|
2017-01-18 |
2019-10-21 |
Genentech Inc |
Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas.
|
|
MX2019008840A
(es)
|
2017-01-25 |
2019-09-09 |
Molecular Templates Inc |
Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
|
|
WO2018159615A1
(en)
|
2017-02-28 |
2018-09-07 |
Chugai Seiyaku Kabushiki Kaisha |
Protein purification with protein l
|
|
DK3592769T3
(da)
|
2017-03-09 |
2024-08-12 |
Genmab As |
Antistoffer mod pd-l1
|
|
WO2018183182A1
(en)
|
2017-03-27 |
2018-10-04 |
Celgene Corporation |
Methods and compositions for reduction of immunogenicity
|
|
EP3689893A4
(en)
|
2017-09-25 |
2021-12-15 |
JSR Corporation |
IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE
|
|
AU2019239850A1
(en)
|
2018-03-19 |
2020-10-29 |
Lanier Biotherapeutics, Inc. |
High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (PD-L1) and uses thereof
|
|
CN110612117B
(zh)
|
2018-04-17 |
2024-04-12 |
分子模板公司 |
包含去免疫化的志贺毒素a亚基支架的her2靶向分子
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
WO2020154475A1
(en)
|
2019-01-23 |
2020-07-30 |
Molecular Templates, Inc. |
Proteins comprising modified immunoglobulin variable light chains
|